MedTrace Logo

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

NCT02898207 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-04-26

Study results available
· View outcomes & findings →

Summary

This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) or ovarian, fallopian tube, primary peritoneal, or triple-negative breast cancer that has come back (recurrent). Olaparib and onalespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Metastatic High Grade Fallopian Tube Serous Adenocarcinoma
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Primary Peritoneal Serous Adenocarcinoma
  • Metastatic Triple-Negative Breast Carcinoma
  • Platinum-Resistant Fallopian Tube Carcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Breast Carcinoma
  • Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
  • Recurrent High Grade Ovarian Serous Adenocarcinoma
  • Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
  • Recurrent Triple-Negative Breast Carcinoma
  • Refractory Fallopian Tube Serous Adenocarcinoma
  • Refractory Ovarian Serous Adenocarcinoma
  • Refractory Primary Peritoneal Serous Adenocarcinoma
  • Refractory Triple-Negative Breast Carcinoma
  • Unresectable High Grade Fallopian Tube Serous Adenocarcinoma
  • Unresectable Malignant Solid Neoplasm
  • Unresectable Primary Peritoneal Serous Adenocarcinoma

Interventions

DRUG

Olaparib

Given PO

DRUG

Onalespib

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Panagiotis A Konstantinopoulos · Dana-Farber - Harvard Cancer Center LAO

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-19
Primary Completion
2020-07-29
Completion
2022-01-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02898207 on ClinicalTrials.gov